Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Epilepsy in brain metastasis: an emerging entity

Abstract

Purpose of review

The purpose of this review is to highlight advances in the management of seizures in brain metastases from solid tumors.

Recent findings

The highest risk for seizures is in patients with melanoma and lung cancer. There is lack of data on the efficacy of antiepileptic drugs (AEDs), but interactions between enzyme-inducing AEDs and anticancer agents must be avoided. Levetiracetam and valproic acid are the most appropriate drugs. Prophylaxis with AEDs for patients with brain metastases without a history of seizures is not recommended. Total resection of a brain metastasis allows complete seizure control. Seizures may represent an adverse effect of stereotactic radiosurgery or of high-dose chemotherapy.

Summary

New preclinical and clinical studies should define the risk of brain metastasis in light of the new treatment options in the different tumor types. New clinical trials should be designed in patients with brain metastases in terms of treatment or prophylaxis of seizures.

This is a preview of subscription content, log in to check access.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.

    Rudà R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol. 2010;22(6):611–20.

  2. 2.

    Soffietti R, Franchino F, Rudà R. Brain metastasis as a complication of systemic cancers. In: Schiff D, Wen PY, editors. Cancer neurology in clinical practice. Heidelberg: Springer; 2017. p. 700–35.

  3. 3.

    Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr. 2002;114(21–22):911–6.

  4. 4.

    • Chan V, Sahgal A, Egeto P, Schweizer T, Das S. Incidence of seizure in adult patients with intracranial metastatic disease. J Neuro-Oncol. 2017;131(3):619–24. An interesting recent retrospective series on the incidence of seizures in brain metastases.

  5. 5.

    Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology. 1998;51(5 Suppl 4):S2–7.

  6. 6.

    Wegman-Ostrosky T, Reynoso-Noverón N, Mejía-Pérez SI, Sánchez-Correa TE, Alvarez-Gómez RM, Vidal-Millán S, et al. Clinical prognostic factors in adults with astrocytoma: historic cohort. Clin Neurol Neurosurg. 2016;146:116–22.

  7. 7.

    Cacho-Diaz B, San-Juan D, Salmeron K, Boyzo C, Lorenzana-Mendoza N. Choice of antiepileptic drugs affects the outcome in cancer patients with seizures. Clin Transl Oncol. 2018;20(12):1571–6.

  8. 8.

    Benit CP, Kerkhof M, Duran-Pena A. Seizures as complications in cancer. In: Schiff D, Wen PY, editors. Cancer neurology in clinical practice. Heidelberg: Springer; 2017. p. 153–69.

  9. 9.

    Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96(3):552–8.

  10. 10.

    Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro-Oncology. 2008;10(2):199–207.

  11. 11.

    Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK. Seizure prophylaxis and melanoma brain metastases. J Neuro-Oncol. 2012;108(1):109–14.

  12. 12.

    Jena A, Taneja S, Talwar V, Sharma JB. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol. 2008;3(2):140–4.

  13. 13.

    Lee MH, Kong DS, Seol HJ, Nam DH, Lee JI. Risk of seizure and its clinical implication in the patients with cerebral metastasis from lung cancer. Acta Neurochir. 2013;155(10):1833–7.

  14. 14.

    Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, et al. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neuro-Oncol. 2004;66(3):313–25.

  15. 15.

    Mongan JP, Fadul CE, Cole BF, Zaki BI, Suriawinata AA, Ripple GH, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer. 2009;8(2):100–5.

  16. 16.

    Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2003;98(2):363–8.

  17. 17.

    • Wu A, Weingart JD, Gallia GL, Lim M, Brem H, Bettegowda C, et al. Risk factors for preoperative seizures and loss of seizure control in patients undergoing surgery for metastatic brain tumors. World Neurosurg. 2017;104:120–8. An interesting review on the seizures in brain metastases following surgery.

  18. 18.

    Duffau H, Capelle L, Lopes M, Bitar A, Sichez JP, van Effenterre R. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir. 2002;144(6):563–73.

  19. 19.

    Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108(2):227–35.

  20. 20.

    Rudà R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, et al. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro-Oncol. 2013;15(12):1739–49.

  21. 21.

    Koekkoek JA, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJ. Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro Oncol. 2015;17(7):924–34.

  22. 22.

    Wernicke AG, Yondorf MZ, Peng L, Trichter S, Nedialkova L, Sabbas A, et al. Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J Neurosurg. 2014;121(2):338–48.

  23. 23.

    Steeghs N, de Jongh FE, Sillevis Smitt PA, van den Bent MJ. Cisplatin-induced encephalopathy and seizures. Anti-Cancer Drugs. 2003;14(6):443–6.

  24. 24.

    Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol. 2002;13(4):629–31.

  25. 25.

    Elkiran ET, Altundag K, Beyazit Y, Guler N, Kars A. Fluorouracil-induced neurotoxicity presenting with generalized tonic-clonic seizure. Ann Pharmacother. 2004 Dec;38(12):2171.

  26. 26.

    Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol. 2019;37(1):52–60.

  27. 27.

    Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neuro-Oncol. 2006;78(1):99–102.

  28. 28.

    Newton HB, Dalton J, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neuro-Oncol. 2007;84:293–6.

  29. 29.

    Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neuro-Oncol. 2008;86(1):61–70.

  30. 30.

    Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neuro-Oncol. 2010;98(1):109–16.

  31. 31.

    Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.

  32. 32.

    Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist. 2014;19(7):751–9.

  33. 33.

    Weller W, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13:375–82.

  34. 34.

    Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013;54(suppl 9):97–104.

  35. 35.

    Bènit CP, Vecht CJ. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine-kinase inhibitors and glucocorticoids. Neuro-oncol Practice. 2016;3(4):245–60.

  36. 36.

    Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13(24):7401–6.

  37. 37.

    Mason WP, MacNeil M, Kavan P, Easaw J, Macdonald D, Thiessen B, et al. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or non receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Investig New Drugs. 2012;30(6):2344–51.

  38. 38.

    Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcome, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65(2):353–61.

  39. 39.

    Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumors: epidemiology, mechanisms and management. Lancet Neurol. 2007;6:421–30.

  40. 40.

    Ohgami M, Kaburagi T, Kurosawa A, Homma M. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with non small cell lung cancer. Lung Cancer. 2016;101:9–10.

  41. 41.

    Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neuro-Oncol. 2005;72(3):255–60.

  42. 42.

    Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB. Potential role for valproate in the treatment of high--risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol. 2011;28(7):556–70.

  43. 43.

    Barker CA, Bishop AJ, Chang M, Beal K, Chan TA. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys. 2013;86(3):504–9.

  44. 44.

    Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology. 2009;73(15):1207–13.

  45. 45.

    Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013;118:859–65.

  46. 46.

    Happold C, Gorlia T, Chinot O, et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. JCO. 2016;34:731–9.

  47. 47.

    Reddy JP, Dawood S, Mitchell M, Debeb BG, Bloom E, Gonzalez-Angulo AM, et al. Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiother Oncol. 2015;117(2):308–14.

  48. 48.

    Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.

  49. 49.

    Perry J, Zinman L, Chambers A, Spithoff K, Lloyd N, Laperriere N. Neuro-oncology Disease Site Group; Cancer Care Ontario’s Program in Evidence-Based Care. The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review. Curr Oncol. 2006;13(6):222–9.

  50. 50.

    Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):97–102.

  51. 51.

    Forsyth PA, Weaver S, Fulton D, Brasher PM, Sutherland G, Stewart D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci. 2003;30(2):106–12.

  52. 52.

    Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013;118(4):873–83.

  53. 53.

    • Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncol. 2017;19(2):162–74. Updated EANO Guidelines on brain metastases.

  54. 54.•

    Wolpert F, Lareida A, Terziev R, et al. Risk factors for the development of epilepsy in patients with brain metastases. Neuro Oncol. 2019. https://doi.org/10.1093/neuonc/noz172. A recent retrospective study on risk of seizures in brain metastases.

Download references

Author information

Correspondence to Roberta Rudà MD.

Ethics declarations

Conflict of Interest

Dr. Roberta Rudà declares that she has no conflict of interest. Dr. Francesca Mo declares that she has no conflict of interest. Dr. Alessia Pellerino declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuro-Oncology

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rudà, R., Mo, F. & Pellerino, A. Epilepsy in brain metastasis: an emerging entity. Curr Treat Options Neurol 22, 6 (2020). https://doi.org/10.1007/s11940-020-0613-y

Download citation

Keywords

  • Brain metastases
  • Seizures
  • Epilepsy
  • Antiepileptic drugs
  • Interactions